In Q2 2026, Bristol Myers Squibb delivered better-than-expected revenues supported by robust sales in immuno-oncology and cell therapy, offsetting continued declines in its legacy drug franchise due to generic competition. Strategic collaborations, including with BioNTech, alongside investments in R&D and manufacturing capacity expansions, reinforce BMS's resilient business model. While generic erosion of legacy assets like Revlimid poses ongoing risks, the diversified portfolio and productivity initiatives provide a sustainable growth pathway.